Abstract
Tacrolimus(FK-506)was first isolated in May 1984 from the culture broth of a soil microorganism found in Tsukuba,Japan.In contrast to Flemming’s penicillin,it was no accidential finding but the result of a thoroughly undertaken screening project for new immunomodulatory substance by researchers of a an industrial company.Following 3 years of extensive research, the first report on this new drug was published by Kino et al. [1]. The newly identified drug-producing fungus was named after its origin as Streptomyces tsukubaensis and is characterized by a grey mycelium color,rectiflexible spore chains with smooth spore surfaces,nonchromogenicity,and a limited carbohydrate usage[2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kino T,Hatanaka H,Hashimoto M et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot Tokyo 40(9): 1249–1255.
Goto T, Kino T, Hatanaka H et al. (1991) FK 506: historical perspectives. Transplant Proc 23:2713–2717.
Tanaka H, Kuroda A, Marusawa H et al. (1987) Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19 [5; Suppl 6]: 11–16
Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y (1987) The oral dosage form of FK-506. Transplant Proc 19 [5; Suppl 6]:17–22
Wesselborg S, Fruman DA, Sagoo JK, Bierer BE, Burakoff SJ (1996) Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem 271:1274–1277.
Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136–142.
Mori A, Suko M, Nishizaki Y et al (1995) IL-5 production by CD4+ T cells of asthmatic patientsis suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 7:449–457
Schneider G, Heinfling A, Klein HS, Schömberg C, Chuvpilo S, Serfling E (1995) The inducible transcription factor NF-AT plays an important role in the activation of the murine interleu- kin-4 promoter. Immunobiology 193:268–272.
Klaus GG, Choi MS, Holman M (1994) Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. Eur J Immunol 24:3229–3232.
Panhans A, Bieber T (1996) FK506 (tacrolimus) impairs the phenotypic and functional differentiation of human epidermal Langerhans cells. J Invest Dermatol 107:485.
Michel G, Ried C, Beetz A (1993) FK-506 blocks expression of interleukin-8 receptor in normal human keratinocytes. J Invest Dermatol 100:449.
de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99:723–728.
Nakajima K, Koichi H, Takaishi T (1992) Antiallergic action of a new immunosuppressive agent, FK 506. Yamanashi Kenritsu Chuo Byoin Nenpo 19:27–30.
Wollenberg A, Kraft S, Hanau D, Bieber T (1996) Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 106:446–453.
Schulz BS, Michel G, Wagner S et al. (1993) Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 151:4399–4406.
Wollenberg A, Regele D, Sharma S, Haberstok J, Panhans A. BieberT(1996) Topical tacrolimus treatment leads to profound alterations of the antigen presenting cells in lesional atopic dermatitis skin. J Invest Dermatol 107:486
Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu EK, Starzl TE (1992) Tacrolimus (FK 506) a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 128:781–785.
The European FK 506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132:419–423.
NakagawaH, EtohT, Ishibashi Y eta! (1994) Tacrolimus ointment lor atopic dermatitis. Lancet 344:8926.
Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H (1995) Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br 1 Dermatol 133:494–496
Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S (1992) Inhibition of contact allergy reactions by topical FK506 (letter). Lancet 340:8818.
Lauerma AI, Stein BD, Homey B, Lee CH, Bloom E, Maibach HI (1994) Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 286:337–340.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wollenberg, A., Bieber, T. (1997). FK-506/Tacrolimus. In: Burg, G., Dummer, R.G. (eds) Strategies for Immunointerventions in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60752-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-60752-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64539-6
Online ISBN: 978-3-642-60752-3
eBook Packages: Springer Book Archive